Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a distinct "exogen" phase in the hair cycle during which hair shedding occurs, primarily coupled with the anagen phase, rather than as part of the telogen phase.

This study suggests that hair shedding, often reported with minoxidil use, is poorly defined in androgenetic alopecia treatment despite its prevalence on social media, highlighting a gap in the literature.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

The document suggests that hair loss after stopping birth control may be similar to post-pregnancy hair loss and could recur with future pregnancies.

The authors concluded that chronic telogen effluvium in middle-aged women presents distinct clinical and histological features that differ from androgenetic alopecia and acute telogen effluvium.

This article reviews common hair growth abnormalities in children, emphasizing the importance of distinguishing normal development from potential signs of metabolic disorders and indicates no new clinical results.

This study found no protective effect of topical calcipotriol on hair loss in chemotherapy patients, and the authors propose the term "atrophic telogen effluvium" for this type of hair loss.

This study reported that etretinate treatment leads to increased hair shedding due to a sustained decrease in anagen duration, with an arrest at the onset of anagen and a follicular anchorage defect in telogen contributing to alopecia.

Telogen effluvium is hair loss caused by disruption of the normal hair cycle.

This article discusses how metabolic imbalances can trigger telogen effluvium by causing hair follicles to prematurely enter the shedding phase, and includes no new research findings.

Hair loss can be linked to hormonal changes, and physical conditions like heart defects can cause depression.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This review discusses the concept of telogen effluvium and emphasizes that its diagnosis requires detailed clinical evaluation and tests to identify underlying causes; no new clinical results are reported.

In this correspondence, the authors reported that patients on a 500-calorie crash diet with rapid weight loss experienced significant hair loss, which began months after dieting and gradually improved.

In this study, researchers discovered that the interaction between the hairless protein and the wise protein is crucial for hair-follicle regeneration, helping bald mice regrow fur.

This study found that a spermidine-based nutritional supplement increased the number of anagen phase hair follicles in healthy humans, suggesting potential benefits for hair loss conditions.

Mimicking growth factors in a topical solution can prolong hair growth phase and reduce hair loss without side effects.

This study found that centrosome ablation in developing epidermis triggers cell surveillance pathways, resulting in thinner skin and halted hair follicle growth, while later stages of epidermal growth may operate independently of basal progenitor division orientation.

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

Hair loss that spreads out can often fix itself or be treated by finding and handling the cause.

This study found that etretinate treatment led to an increase in plucked telogen hair counts, suggesting a reduction in the duration of anagen as the primary cause.

A horse's sudden hair loss was caused by an allergic reaction to a coat conditioning powder.

This review discusses telogen effluvium as a common cause of diffuse hair loss and reports no new clinical results, noting diagnostic and treatment challenges.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

This article reviews the role of epithelial-mesenchymal interactions in hair follicle morphogenesis and the hair cycle, suggesting potential paths for developing treatments for hair growth disorders but providing no new clinical findings.

This review outlines the classification, histopathologic presentation, and pathogenetic concepts of scarring and nonscarring alopecias, reporting no new clinical results and emphasizing the need for clinicopathologic correlation.

This study observed that eliminating positional error in hair segment analysis can improve understanding of changes in isotopic composition, aiding the identification of pathological conditions and dietary patterns.

This review discusses the various triggers and diagnostic challenges in determining the cause of telogen effluvium-related hair loss, without providing new clinical results.

The study reports that Fgf18 and Tgf-β2 signaling pathways in hair follicle stem cells have opposing effects on the timing of hair cycle transitions, influencing the shift from telogen to anagen phases.